Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[CDK and MMP inhibitors]

A Okuyama1, T Akiyama, M Nakajima

  • 1Banyu Tsukuba Research Institute, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 6, 1997
PubMed
Summary

Butyrolactone I, a CDK inhibitor, halts cell cycle progression and DNA replication. MMP inhibitors like BE16627B and Marimastat show promise in inhibiting tumor growth and extending patient survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.

Lupus·2017
Same author

The relation between sexual interest and personality characteristics in men: an eye-tracking study.

International journal of impotence research·2010
Same author

Metabolism of amyloid precursor protein in COS cells transfected with a beta-secretase candidate.

Cytotechnology·2008
Same author

Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants.

Transplantation proceedings·2008
Same author

Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer.

British journal of cancer·2007
Same author

Isolation of germ cells from leukemic cells.

Human reproduction (Oxford, England)·2007

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncology

Context:

  • Cyclin-dependent kinases (CDKs) regulate the cell cycle.
  • Matrix metalloproteinases (MMPs) are implicated in tumor growth and metastasis.

Purpose:

  • To investigate the effects of Butyrolactone I, a CDK inhibitor, on cell cycle progression.
  • To evaluate the efficacy of MMP inhibitors (BE16627B and Marimastat) in preclinical and clinical settings.

Summary:

  • Butyrolactone I inhibits CDK1, 2, and 5, blocking G1/S and G2/M transitions by preventing RB protein and H1 histone phosphorylation, respectively. It also selectively inhibits DNA replication initiation.
  • BE16627B, an MMP inhibitor, reversibly inhibits metalloproteinases, demonstrating MMP-dependent suppression of human tumor cell growth and metastasis in mice without cytotoxicity.
  • Marimastat, another MMP inhibitor, significantly prolonged the survival of pancreatic cancer patients in clinical trials.

Impact:

  • These findings highlight the therapeutic potential of CDK and MMP inhibitors in cancer treatment.
  • Butyrolactone I offers a novel strategy for cell cycle control in cancer therapy.
  • MMP inhibitors demonstrate a promising, well-tolerated approach to combatting cancer progression and metastasis.

Related Experiment Videos